WallStreetZenWallStreetZen

NASDAQ: BNTX
Biontech Se Stock

$142.06-2.34 (-1.62%)
Updated Feb 3, 2023
BNTX Price
$142.06
Fair Value Price
$193.84
Market Cap
$34.52B
52 Week Low
$117.08
52 Week High
$189.07
P/E
3.42x
P/B
1.92x
P/S
1.77x
PEG
N/A
Dividend Yield
1.49%
Revenue
$18.20B
Earnings
$10.32B
Gross Margin
81.7%
Operating Margin
78.18%
Profit Margin
55.6%
Debt to Equity
0.23
Operating Cash Flow
$13B
Beta
0.86
Next Earnings
Mar 27, 2023
Ex-Dividend
N/A
Next Dividend
N/A

BNTX Overview

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BNTX scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BNTX ($142.06) is undervalued by 26.71% relative to our estimate of its Fair Value price of $193.84 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BNTX ($142.06) is significantly undervalued by 26.71% relative to our estimate of its Fair Value price of $193.84 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BNTX is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more BNTX due diligence checks available for Premium users.

Be the first to know about important BNTX news, forecast changes, insider trades & much more!

BNTX News

Valuation

BNTX fair value

Fair Value of BNTX stock based on Discounted Cash Flow (DCF)
Price
$142.06
Fair Value
$193.84
Undervalued by
26.71%
BNTX ($142.06) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BNTX ($142.06) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BNTX is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BNTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
3.42x
Industry
10.7x
Market
15.09x
BNTX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BNTX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

BNTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.92x
Industry
5.11x
BNTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BNTX's financial health

Profit margin

Revenue
$3.5B
Net Income
$1.8B
Profit Margin
51.6%
BNTX's Earnings (EBIT) of $14.23B... subscribe to Premium to read more.
Interest Coverage Financials
BNTX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$22.7B
Liabilities
$4.3B
Debt to equity
0.23
BNTX's short-term assets ($20.85B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BNTX's short-term assets ($20.85B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BNTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$4.8B
Investing
-$83.3M
Financing
-$653.4M
BNTX's operating cash flow ($12.30B)... subscribe to Premium to read more.
Debt Coverage Financials

BNTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
BNTX$34.52B-1.62%3.42x1.92x
ALNY$28.71B+1.58%-23.89x-424.48x
BGNE$26.70B+0.73%-155.70x5.74x
SGEN$25.62B-1.03%-40.00x9.08x
GMAB$25.19B-0.29%33.44x7.14x

Biontech Se Stock FAQ

What is Biontech Se's quote symbol?

NASDAQ: BNTX) Biontech Se trades on the NASDAQ under the ticker symbol BNTX. Biontech Se stock quotes can also be displayed as NASDAQ: BNTX.

If you're new to stock investing, here's how to buy Biontech Se stock.

What is the 52 week high and low for Biontech Se (NASDAQ: BNTX)?

(NASDAQ: BNTX) Biontech Se's 52-week high was $189.07, and its 52-week low was $117.08. It is currently -24.87% from its 52-week high and 21.34% from its 52-week low.

How much is Biontech Se stock worth today?

(NASDAQ: BNTX) Biontech Se currently has 243,019,216 outstanding shares. With Biontech Se stock trading at $142.06 per share, the total value of Biontech Se stock (market capitalization) is $34.52B.

Biontech Se stock was originally listed at a price of $14.24 in Oct 10, 2019. If you had invested in Biontech Se stock at $14.24, your return over the last 3 years would have been 897.61%, for an annualized return of 115.27% (not including any dividends or dividend reinvestments).

How much is Biontech Se's stock price per share?

(NASDAQ: BNTX) Biontech Se stock price per share is $142.06 today (as of Feb 3, 2023).

What is Biontech Se's Market Cap?

(NASDAQ: BNTX) Biontech Se's market cap is $34.52B, as of Feb 7, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Biontech Se's market cap is calculated by multiplying BNTX's current stock price of $142.06 by BNTX's total outstanding shares of 243,019,216.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.